5 15 25 20 10 Ct value Log concentration miR-375 miR-221 Supplementary Figure S1.

Slides:

Advertisements

Similar presentations

Neoadjuvant Chemotherapy in Malignant Peripheral Nerve Sheath Tumors Elizabeth Shurell, M.D., M.Phil. UCLA General Surgery Resident Research Fellow, Division.

Advertisements

Tumor Markers Lecture one By Dr. Reem Sallam. Objectives  To briefly introduce cancers, their incidence, some common terms, and staging system.  To.

 - an important step in surgical staging for uterine cancer (FIGO 1988)  Stated as 

Injection of intra arterial methylene blue ex-vivo in colorectal cancer specimens increase lymph node harvest Colorectal unit – University Hospital of.

PREOPERATIVE PLASMA CONCENTRATION OF MMP-9/TIMP-1 COMPLEXES IS NOT ASSOCIATED WITH DISEASE OUTCOME IN PRIMARY BREAST CANCER (N=483) Anne-Sofie Schrohl.

Characteristics of submucosal gastric carcinoma with lymph node metastatic disease H J Son, S Y Song,1 S Kim,3 J H Noh,2 T S Sohn,2 D S Kim1 & J C Rhee.

Geonomics in Breast Cancer Decoding Human Genome Luis Barreras, M.D., FACP.

Suppl. Figure 1 A B Suppl. Figure 1. Relative (A) miR-21 and (B) miR-224 expression levels in HCC tumors in different stages (I,II,III,IV) assessed by.

57445 HCC were registered HCC with complete data underwent surgical resection 9577 underwent local ablation therapies 9283 underwent TACE 1150.

Supplementary Table 1 Table S1. Population frequency of HLA -A, -B and -C alleles. Rare alleles (frequency < 0.5%) are highlighted by a grey background.

Cancer Deregulation of cell cycle Loss of control of mitosis Result of mutation Over 200 types of cancer exists (Number of cancer cases will double by.

TRAB/2FTRAB/2O A Normal Breast Epithelium Supplemental Figure 1 iii iii iv TRAB/2FTRAB/2O GFs B M.W. None=0

Intergroup trial CALGB 80101

Kerrington Smith, M.D. CTOS Nov 14, 2008

PANCREATIC CANCER.

Xenograft TDDoxorubicinCisplatinIfosfamide SGDT/C%EfficacySGDT/C%EfficacySGDT/C%Efficacy OHS > CTPX > SBX6, >

Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain.

An Assessment of Factors Affecting Outcome in Patients Presenting with Metastatic Soft Tissue Sarcoma Peter Ferguson MD1,2, Benjamin Deheshi MD1,2, Anthony.

Table S1. Demographics and Patient Pathology Results Total number of patients40 Male (%)29 (72%) Female (%)11 (28%) Age Range47 – 86 Median Age70 Organ.

MicroRNA implication in urinary bladder cancer A. Zaravinos 1, J. Radojicic 3, G.I. Lambrou 2, D. Volanis 1,4, D. Delakas 4, E.N. Stathopoulos 3, D.A.

Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis Daniel J. Sargent,

吳華席 Hua-Hsi Wu, MD OB/GYN, VGH-TPE Aug 12, 2008

Age, SexHistologyPredominant subtype Pathological stage EGFR mutation CAF1 61, MaleAdenocarcinoma Solid predominant pT3N2M0 L858R CAF2 71, MaleAdenocarcinoma.

© Cancer Research UK 2006 Registered charity number The statistics in this presentation are based on the Bowel CancerStats report published in.

Supplementary table 1 Supplementary table 1. Clinical-pathological features of the resection-only and chemotherapy/resection stage II/III colorectal cancer.

Supplementary table 1 miR-506 expression and clinocopathological factors FactorsTotal number miR-506 low expressionmiR-506 high expression P-value (n =

© Cancer Research UK 2006 Registered charity number Bladder Cancer The statistics in this presentation are based on the Bowel CancerStats report.

Cmab might have therapeutic benefit in Japanese patients with KRAS p.G13D mutant colorectal cancer. Limitations of this study are its retrospective design.

ADT, Estramustine, Dexamethasone Prednisolone Radiotherapy (Months) (ng/mL) PSA Time Patient A Patient B Patient.

Ki-67 index cutoff value of 1% is a valuable prognostic biomarker for pulmonary carcinoids based on this large cohort. Our data also provide strong evidence.

Supplementary Table S1. Patient demographics of the RRBS discovery set. Characteristics RRBS discovery set TotalIDH1/2 WT IDH1 MUT No. of Patients

Should liver metastases of breast cancer be biopsied to improve treatment choice? M. A. Locatelli, G. Curigliano, L. Fumagalli, V. Bagnardi, G. Aurilio,

Supplemental Digital Content Figure 1A A Academic/Research Program Extent of Lung Resection No. of SubjectEventCensored Median Survival (95% CI)60 mo Survival.

The Influence of Age on Morbidity in Primary High Grade Sarcoma of the Extremity K. Alektiar, M. Brennan, S. Singer Memorial Sloan-Kettering Cancer Center.

Role of Sentinel Lymph Node Biopsy in the Staging of Synovial, Epithelioid, and Clear Cell Sarcomas. Ugwuji N. Maduekwe, Francis J. Hornicek, Dempsey S.

Oral squamous cell carcinoma. A malignancy of epithelial cells Oral and oropharyngeal SCC represent about 3% of cancers in men and 2% of cancers in women.

Discussant Slides: Title: Radiosensitivity Index Shows Promise for Predicting Outcomes with Adjuvant Radiation in Resected Pancreatic Cancer Patients Poster.

Supplementary Table 1: Clinicopathologic characteristics of 100 patients with invasive breast cancer Clinical characteristicsNumber of cases (%) Median.

Pancreatic Tumors in Children Presented by Damien W. Carter, MD.

Preoperative staging of hilar cholangiocarcinoma by dual-modality PET/CT. DR SIKANDAR YASHODA HOSPITALS HYDERABAD.

Case 1. Diagnosis : Stomach, resection margin, proximal, FS-1, biopsy: No tumor Stomach, resection margin, distal, FS-2, biopsy: Adenocarcinoma Lymph.

Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor with a complex growth pattern. Imaging plays a crucial role in diagnosis.

Addition of Chemotherapy to Preoperative Radiotherapy Improves Outcomes in Rectal Cancer Slideset on: Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal.

ADVERSE PROGNOSTIC FACTORS IMPACTING SURVIVAL IN RESECTED INVASIVE, MUCINOUS CYSTADENOCARCINOMAS OF THE PANCREAS Stephen J. Ko 1, Michele M. Corsini 2,

Main Figures and Tables

Number of brain metastasis

Fig 1A. Patient enrollment flow chart

Circulating microRNAs as novel minimally invasive biomarkers for breast cancer Supplementary Information Helen M. Heneghan1, Nicola Miller1, Aoife J.

Ke Xu, Ph.D. Putuo Hospital and Cancer Institute,

Prognosis of younger patients in non-small cell lung cancer

European Urology Focus

Staging Cancer.

Cancer Staging.

Circulating MicroRNAs as Biomarkers of Colorectal Cancer: Results From a Genome- Wide Profiling and Validation Study María Dolores Giráldez, Juan José.

Plasma MicroRNA-21 Is Associated with Tumor Burden in Cutaneous Melanoma Gerald Saldanha, Linda Potter, Priya Shendge, Joy Osborne, Steve Nicholson, NgiWieh.

UHRF1 is regulated by miR-9 in colorectal cancer

Andrew Feber, PhD, Liqiang Xi, MD, PhD, Arjun Pennathur, MD, William E

A B Yeom Supplementary Fig.2

Disease-specific survival

Table S1. Inverse correlation between FOXC2 and PP2A/C expression (tested by one-tailed Spearman's nonparametric correlation test, correlation coefficient.

Volume 137, Issue 2, Pages e11 (August 2009)

Leukocytes in human PDAC

Serum LAMC2 levels in pancreatic adenocarcinoma (PDAC) and other samples from Japan. Serum LAMC2 levels in pancreatic adenocarcinoma (PDAC) and other samples.

Intratumoral Heterogeneity of MicroRNA Expression in Breast Cancer

Treated with Neoadjuvant Therapy

Supplementary Table S2 Correlation between pre-operative plasma miR-451 or miR-486 concentrations and clinicopathologic features in gastric cancer patients.

Healthy volunteers (n=28) P value CRC patients 　　　　　　　 (n=30) ±9.3

Figure S1. A. B. Figure S1. Kaplan-Meier curve of progression-free survival by treatment group in soluble heregulin (HRG)-high population (A) and soluble.

Fig. 1. Classification of the Kaplan-Meier curves and Cox survival estimates for the OS of patients using the pSPC in Cohort_C and in the overall population.

NUAK1 overexpression correlates with tumor progression, lymph node infiltrates, and reduced overall survival (OS) in human colorectal cancer. NUAK1 overexpression.

Presentation transcript:

Ct value Log concentration miR-375 miR-221 Supplementary Figure S1

Supplementary Figure S2 T-Bil CA19-9 AMY miR-221 concentration (amol/μl)

VariablesPatients (n=47) miR-221 Concentration (amol/μ ｌ ) p-value a Age (year)mean (range)67 (42-84) ≤6516( 34.0% )3.31E ≥6631( 66.0% )4.29E-02 Sex Male 27( 57.4% )4.10E Femal20( 42.6% )4.29E-02 Histopathology Adenocarcinoma 42( 89.4% )4.38E Others5( 10.6% )2.56E-02 Location Ph34( 72.3% )4.15E Pb/Pt13( 27.7% )3.44E-02 Depth of invasion T0/1/27( 14.9% )2.87E T3/440( 85.1% )4.17E-02 Lymph node metastasis Negative17( 36.2% )3.71E Positive30( 63.8% )4.27E-02 Distant metastasis Negative38( 80.9% )3.42E Positive9( 19.1% )6.08E-02 Stage 0- Ⅱ A 16( 34.0% )3.54E Ⅱ B- Ⅳ 31( 66.0% )4.23E-02 Treatment Resectable37( 78.7% )3.47E Non-resectable10( 21.3% )5.75E-02 Characteristics and plasma miR-221 concentrations of 47 consecutive PCa patients NOTE. Significant values are in boldface type. a P values are from the Mann-Whitney U-test and were considered significant at Supplementary Table S1

Supplementary Table S2 Plasma miR-221 concentration (amol/μl) SamplenMean95% CI b p-value c Pancreatic cancer p < Benign tumor a p = Normal control a Five IPMNs, 2 serous cystadenomas, and 2 pancteatitis tumors were included in benign tumors. b 95% confidential interval c Plasma concentrations of each group were compared with those of normal controls by Mann-Whitney U test. Differential expression pattern of plasma miR-221 in patients with pancreatic, pancreatic benign tumors, and normal controls

Plasma miR-221Tumor miR-221 High plasma miR-221 cases a Concentration (amol/μl)Tumor expressionmiR-221/U6B ratio 11.94E-01high E-01high E-02high E-02high E-02high E-02high1.34 Rate reflecting tumor dynamics100% b a Cut-off value of plasma miR-221 concentrations in healthy volunteers (mean+2SD): 4.047E-02 amol/μl b Cut-off value of miR-221/U6B ratios in normal pancreatic tissues (median): 1.00 Relationship between miRNA-221 in plasma and pancreatic cancer tissues Supplementary Table S3